BMC Neuroscience

official impact factor 3.09
Search for
Advanced search
BMC Neuroscience
Tools
Share this article

This article is part of the supplement: Proceedings of the 8th International Conference on Alzheimer's Disease Drug Discovery

Open Access Highly Access

Hypometabolism as a therapeutic target in Alzheimer's disease

Lauren C Costantini*, Linda J Barr, Janet L Vogel and Samuel T Henderson

BMC Neuroscience 2008, 9(Suppl 2):S16 doi:10.1186/1471-2202-9-S2-S16

Accesses  

  • Last 30 days: 161 accesses
  • Last 365 days: 1620 accesses
  • All time: 6029 accesses

Cited by

BioMed Central: 2 citations

Research article   Open Access

Enhancement of L-3-hydroxybutyryl-CoA dehydrogenase activity and circulating ketone body levels by pantethine. Relevance to dopaminergic injury

Emilie Cornille, Mhamad Abou-Hamdan, Michel Khrestchatisky, André Nieoullon, Max de Reggi, Bouchra Gharib BMC Neuroscience 2010, 11:51 (23 April 2010)

Abstract | Full text | PDF | PubMed

Research   Open Access

Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial

Samuel T Henderson, Janet L Vogel, Linda J Barr, Fiona Garvin, Julie J Jones, Lauren C Costantini Nutrition & Metabolism 2009, 6:31 (10 August 2009)

Abstract | Full text | PDF | PubMed

Google Scholar: View citations

ISI Web of Science: View citations

PubMed Central: View citations